Pharma Equity Group
0.174
DKK
+2.65 %
PEG
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
13 following
+2.65%
+8.41%
-29.27%
-27.5%
-59.53%
-56.28%
-42%
-79.59%
-99.33%
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Read moreMarket cap
213.59M DKK
Turnover
245.18K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Latest research
Latest analysis report
Released: 28.10.2024
ShowingAll content types
Pharma Equity Group: Opdatering på pipeline
The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
The Board of Directors' decision on a new execution strategy and prioritisation of clinical areas in Reponex Pharmaceuticals A/S.
Dagens aktienyheder 29/11: Penneo, AUDIENTES, RTX, Asetek og Pharma Equity Group
Martin Engell-Rossen will be Head of Cabinet to Denmark's new EU Commissioner Dan Jørgensen in Brussels and will therefore resign from the Board of Directors of Pharma Equity Group A/S
Martin Engell-Rossen skal fremover være kabinetschef for Danmarks nye EU-kommissær Dan Jørgensen i Bruxelles og udtræder derfor af bestyrelsen i Pharma Equity Group A/S
Dagens aktienyheder 18/11: SP Group, Gabriel, Pharma Equity Group, Curasight og Scandinavian Medical Solutions
Pharma Equity Group: Opdatering fra interview med CEO Thomas K. Selsø
Pharma Equity Group – Gennemgang af 3. kvartal og styrkelsen af selskabets kapitalstruktur
Konsolideret delårsrapport 1. januar – 30. september 2024
Consolidated Interim report 1 January – 30 September 2024
Dagens aktienyheder 29/10: NTG | Nordic Transport Group A/S, Green Hydrogen Systems, BioPorto A/S og Pharma Equity Group A/S
Pharma Equity Group (One-pager): Capital position strenghtened
Dagens aktienyheder 24/10: Skjern Bank, MapsPeople, BioPorto, Pharma Equity Group og Audientes
Pharma Equity Group’s datterselskab (Reponex Pharmaceuticals A/S) har opnået patentbeskyttelse i Japan på behandling af colorectal cancer med RNX-051.
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051.
